Position in CYTK
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$119,033
+$2,565 QoQ
Shares Held
1,806
-1.5% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2023
9 quarters on record
Voting authority
Sole 0.ToString("F0")%
Shared 0.ToString("F0")%
None 100.ToString("F0")%
Common Shares in CYTK Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Larson Financial Group LLC holds $4,055,906 across 194 Biotechnology names. CYTK ranks #7 (2.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
1,319 | $588,986 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
561 | $433,451 | |
| 3 | TGTX |
Tg Therapeutics, Inc.
|
7,490 | $248,817 | |
| 4 | IONS |
Ionis Pharmaceuticals Inc
|
3,031 | $227,597 | |
| 5 | EXEL |
Exelixis, Inc.
|
4,433 | $190,131 | |
| 6 | INCY |
Incyte Corp
|
1,602 | $150,780 | |
| 7 | CYTK |
Cytokinetics Inc
This page
|
1,806 | $119,033 | |
| 8 | MRNA |
Moderna, Inc.
|
2,166 | $110,032 |
All Filings in CYTK
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $119,033 | 1,806 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $116,468 | 1,833 | Shares | Sole | 2026-02-06 | |
| 2025-09-30 | $101,785 | 1,852 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $12,026 | 364 | Shares | Sole | 2025-08-08 | |
| 2025-03-31 | $2,692 | 67 | Shares | Sole | 2025-05-02 | |
| 2024-12-31 | $141 | 3 | Shares | Sole | 2025-02-07 | |
| 2023-09-30 | $8,838 | 300 | Shares | Sole | 2023-11-03 | |
| 2023-06-30 | $4,762 | 146 | Shares | Sole | 2023-08-03 | |
| 2023-03-31 | $5,137 | 146 | Shares | Sole | 2023-05-04 | |
| No filing history on record for this holder in this stock. | ||||||